Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MOREWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MOREUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don’t find the answers you’re looking for, contact us for additional assistance.
EXPLORE MOREChimeric antigen receptors (CARs) are designed to attach to specific proteins to reprogram T cells to kill cancer. The success of CAR-T cell therapy highlights the prospect of programmed immunity and suggests that applying CAR strategies to other immune cell lineages may be beneficial. As a leading technology provider, Creative Biolabs has established the CellRapeutics™ chimeric engulfment receptor (CER) technology platform for phagocytosis, which directs macrophages to engulf specific targets on cancer cells.
Significance of Macrophage-mediated Phagocytosis
Macrophages are a key effector of the innate immune system and are responsible for engulfing debris and pathogens. A variety of evidence shows that macrophages have the unique ability to penetrate solid tumors and fight tumor growth, while other immune cells (such as T cells) are physically rejected or inactivated. This suggests that engineered macrophages may enhance existing T cell-based cell therapies.
Another supporting finding is that antibody blocking of the negative regulator of phagocytosis, CD47, reduces tumor burden, suggesting that metastatic balance to promote macrophage activation and phagocytosis is a promising therapeutic approach. Therefore, our innovative CER-macrophage therapy holds broad therapeutic prospects in the future.
Fig.1 Role of tumor-associated macrophages (TAMs) in cancer.
CER Design and Construction
We have developed different generations of CERs. Similar to CAR, our CERs essentially consist of three modules: the extracellular domain targeting (ECD) targeting the phagocytic target antigen, transmembrane domain (TMD) and phagocytosis intracellular signaling domain (ESD). The ECD protein can be scFv, Fab, VHH, peptide, or sometimes an FcR. The ESD of our second-generation CER includes a primary phagocytic signal domain and a secondary phagocytic signal domain.
Fig.2 Schematic of the structure of CER constructs.
One-stop CER-MA Development Services
Empowered by our high qualified groups and advanced technologies, Creative Biolabs provides one-stop CER-MA development services:
It should be noted that our CER can not only genetically modify macrophages, but also modify the phagocytic phenotype of cells that do not naturally show phagocytic activity, including T cells, natural killer cells, natural killer T cells, B cells, somatic cells, dendritic cells, Langerhans cells, and bone marrow cells.
For more detailed information, please feel free to contact us or directly sent us an inquiry.
Reference
For any technical issues or products/services related questions, please leave your information below. Our team will contact you soon.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.
LEARN MORE
Angiotensin-converting Enzyme 2 (ACE2)-CHO Cell Line Model for COVID-19: Helps researchers to further study the interaction between the receptor ACE2 and the COVID-19 virus.
LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.
LEARN MORE
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE
